In a two-center retrospective cohort study evaluating children undergoing maintenance hemodialysis, researchers found no statistically detectable difference in six-month adjusted hemoglobin levels between patients receiving oral iron and those treated with intravenous iron supplementation. The investigation evaluated whether the route of iron administration influenced hematologic recovery and iron-status parameters over a six-month observation window among thirty pediatric patients.
Anemia represents a frequent and clinically significant complication in pediatric patients diagnosed with chronic kidney disease, particularly among individuals requiring regular maintenance hemodialysis. While supplemental iron therapy is recognized as essential for optimizing erythropoiesis in this clinical cohort, the optimal route of administration—comparing oral versus intravenous regimens—has remained an ongoing subject of debate within pediatric nephrology practice.
Conducted across two tertiary medical centers, the retrospective study examined thirty pediatric maintenance-hemodialysis patients who were administered individualized iron regimens based on the clinical discretion of their treating physicians. Among the overall cohort, fifteen children were assigned to receive intravenous iron supplementation, while the remaining fifteen children received oral iron therapy under individualized management protocols.
The primary endpoint of the investigation was hemoglobin concentration measured at six months, analyzed through analysis of covariance comparing oral with intravenous iron while adjusting for baseline hemoglobin, dialysis vintage, and log-transformed baseline C-reactive protein using HC3 robust standard errors. Across unadjusted evaluations, mean hemoglobin rose by 0.67 ± 1.76 g/dL in the intravenous iron cohort and by 1.76 ± 2.45 g/dL in the oral iron cohort, reflecting a direct between-group difference in change of 1.09 g/dL with a 95% confidence interval ranging from −0.52 to 2.69 g/dL (P = 0.175). In the primary adjusted analysis encompassing twenty-eight patients with complete data, the oral-minus-intravenous difference in six-month hemoglobin was 1.31 g/dL with a 95% confidence interval of −0.56 to 3.18 g/dL (P = 0.161), and all corresponding sensitivity analyses similarly yielded non-significant findings.
Secondary outcomes assessed across the six-month study period included serum ferritin, transferrin saturation, other iron-status indices, epoetin alfa utilization, treatment-related complications, and packed-cell blood transfusions. Serum ferritin concentrations demonstrated increases within both treatment arms, though the between-group difference in change did not achieve statistical significance. While an exploratory unadjusted change-score calculation suggested a greater increase in transferrin saturation among oral iron recipients, this baseline-adjusted comparison did not remain statistically significant following false-discovery-rate correction. Complications were documented in eight of fifteen oral iron recipients and seven of fifteen intravenous recipients (P = 1.000), packed-cell transfusions were administered to two oral iron patients and six intravenous iron patients (P = 0.215), and no serious adverse events were documented in either group.
In their concluding assessment, the study authors emphasized that the observed lack of a statistically detectable difference in adjusted six-month hemoglobin must be interpreted with caution. The small overall cohort size, wide confidence intervals, baseline imbalances between arms, individualized treatment selection by treating clinicians, and the potential presence of residual confounding preclude definitive conclusions regarding the superiority, clinical equivalence, or preferred route of iron administration in pediatric hemodialysis care.
Subject of Research: Oral versus intravenous iron supplementation outcomes in pediatric hemodialysis
Article Title: Oral versus intravenous iron supplementation and six-month hemoglobin and iron-status outcomes in pediatric hemodialysis: a two-center retrospective cohort study
Article References: Voshtani, S., Bahroudi, M., Mojtahedi, S. Y., Moghtaderi, M., Safari, A., Fahimi, D., Askarian, F., Abbasi, A., & Bazargani, B. (2026). Oral versus intravenous iron supplementation and six-month hemoglobin and iron-status outcomes in pediatric hemodialysis: a two-center retrospective cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07834-y
Image Credits: AI Generated
DOI: 10.1186/s12887-026-07834-y
Keywords: pediatric hemodialysis, oral iron, intravenous iron, chronic kidney disease, anemia, hemoglobin, ferritin, transferrin saturation, erythropoiesis, epoetin alfa, dialysis vintage, C-reactive protein, packed-cell transfusion, retrospective cohort study, tertiary centers, iron supplementation
News Source: Harold Sullivan. (November 12, 2026). Pediatric Hemodialysis Study Finds No Significant Hemoglobin Difference Between Iron Routes. Scienmag.



